Review



erbb3 speci c  (Santa Cruz Biotechnology)


Bioz Verified Symbol Santa Cruz Biotechnology is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Santa Cruz Biotechnology erbb3 speci c
    Figure 3 Tyrosine phosphorylation of <t>ErbB3</t> in response to NDF and BTC but not EGF. SKBR3 cells were treated with 1 nM of the indicated ligands for 10 min and lysed. ErbB3 was immunoprecipitated from 1 mg total lysate using C17 antiserum, subjected to SDS ± PAGE, blotted and probed with an anti- phosphotyrosine mAb. The membrane was then stripped and reprobed with ErbB3 speci®c C17 serum
    Erbb3 Speci C, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 481 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/erbb3+speci+c/ErbB-3+Antibody/pm10376522-257-12-19
    Average 93 stars, based on 481 article reviews
    erbb3 speci c - by Bioz Stars, 2026-09
    93/100 stars

    Images

    1) Product Images from "NDF/heregulin-induced cell cycle changes and apoptosis in breast tumour cells: role of PI3 kinase and p38 MAP kinase pathways."

    Article Title: NDF/heregulin-induced cell cycle changes and apoptosis in breast tumour cells: role of PI3 kinase and p38 MAP kinase pathways.

    Journal: Oncogene

    doi: 10.1038/sj.onc.1202700

    Figure 3 Tyrosine phosphorylation of ErbB3 in response to NDF and BTC but not EGF. SKBR3 cells were treated with 1 nM of the indicated ligands for 10 min and lysed. ErbB3 was immunoprecipitated from 1 mg total lysate using C17 antiserum, subjected to SDS ± PAGE, blotted and probed with an anti- phosphotyrosine mAb. The membrane was then stripped and reprobed with ErbB3 speci®c C17 serum
    Figure Legend Snippet: Figure 3 Tyrosine phosphorylation of ErbB3 in response to NDF and BTC but not EGF. SKBR3 cells were treated with 1 nM of the indicated ligands for 10 min and lysed. ErbB3 was immunoprecipitated from 1 mg total lysate using C17 antiserum, subjected to SDS ± PAGE, blotted and probed with an anti- phosphotyrosine mAb. The membrane was then stripped and reprobed with ErbB3 speci®c C17 serum

    Techniques Used: Phospho-proteomics, Immunoprecipitation, SDS Page, Membrane

    Figure 5 Comparison of signal transduction by NDF and BTC. SKBR3 cells were treated with 1 nM of NDF or BTC for the indicated times or left untreated (con). (a, b) 70 mg total lysate was subjected to SDS ± PAGE, blotted and probed with antisera speci®c for the active forms of ERK 1 and 2 (a). The blot was stripped and then probed for the active forms p38 MAPK (b). (c) ErbB3 was immunoprecipitated from 1 mg total lysate, subjected to SDS ± PAGE, blotted and probed with antiserum speci®c for the p85 subunit of PI3K. (d) 50 mg total lysate was subjected to SDS ± PAGE, blotted and probed with antisera speci®c for the active form of PKB
    Figure Legend Snippet: Figure 5 Comparison of signal transduction by NDF and BTC. SKBR3 cells were treated with 1 nM of NDF or BTC for the indicated times or left untreated (con). (a, b) 70 mg total lysate was subjected to SDS ± PAGE, blotted and probed with antisera speci®c for the active forms of ERK 1 and 2 (a). The blot was stripped and then probed for the active forms p38 MAPK (b). (c) ErbB3 was immunoprecipitated from 1 mg total lysate, subjected to SDS ± PAGE, blotted and probed with antiserum speci®c for the p85 subunit of PI3K. (d) 50 mg total lysate was subjected to SDS ± PAGE, blotted and probed with antisera speci®c for the active form of PKB

    Techniques Used: Comparison, Transduction, SDS Page, Immunoprecipitation

    Related Articles

    Phospho-proteomics:

    Article Title: NDF/heregulin-induced cell cycle changes and apoptosis in breast tumour cells: role of PI3 kinase and p38 MAP kinase pathways.
    Article Snippet: Recombinant human ErbB ligands included NDF (Neomarkers, Fremont, CA, USA), EGF (Sigma) and BTC (R & D Systems).included NDF (Neomarkers, Fremont, CA, USA), EGF (Sigma) and BTC (R & D Systems). ... Antibodies used were: ErbB2 speci®c 21N polyclonal antiserum (Hynes et al., 1989), ErbB3 speci®c a nity-puri®ed polyclonal antiserum C17 (Santa Cruz Biotechnology), phosphotyrosine-speci®c mAb, p85-speci®c antiserum (UBI), c-Src speci®c Ab-1 mAb (Calbiochem), anti-phospho-speci®c p38a and p38b/b2 MAPK (Thr180/ Tyr182) polyclonal antiserum, anti-phospho-speci®c p44/42 ERK (Thr202/Tyr204) polyclonal antiserum, anti-phosphospeci®c Akt/PKB (Ser473) polyclonal antiserum, antiphospho-speci®c Cdc2 (Cdk1) (Tyr15) polyclonal antiserum (New England Biolabs MA, USA), anti-Cdc2 polyclonal antiserum (Gibco), anti-cyclin A polyclonal antiserum (Lisztwan et al., 1998, supplied by W Krek, FMI), and anti cyclin B1 polyclonal antiserum, H-433 (Santa Cruz).. Speci®c kinase inhibitors were stored as 1000 ± 5000 times concentrated stock solutions in DMSO and usually added 90 min prior to ligand treatment.Speci®c kinase inhibitors were stored as 1000 ± 5000 times concentrated stock solutions in..

    Immunoprecipitation:

    Article Title: NDF/heregulin-induced cell cycle changes and apoptosis in breast tumour cells: role of PI3 kinase and p38 MAP kinase pathways.
    Article Snippet: Recombinant human ErbB ligands included NDF (Neomarkers, Fremont, CA, USA), EGF (Sigma) and BTC (R & D Systems).included NDF (Neomarkers, Fremont, CA, USA), EGF (Sigma) and BTC (R & D Systems). ... Antibodies used were: ErbB2 speci®c 21N polyclonal antiserum (Hynes et al., 1989), ErbB3 speci®c a nity-puri®ed polyclonal antiserum C17 (Santa Cruz Biotechnology), phosphotyrosine-speci®c mAb, p85-speci®c antiserum (UBI), c-Src speci®c Ab-1 mAb (Calbiochem), anti-phospho-speci®c p38a and p38b/b2 MAPK (Thr180/ Tyr182) polyclonal antiserum, anti-phospho-speci®c p44/42 ERK (Thr202/Tyr204) polyclonal antiserum, anti-phosphospeci®c Akt/PKB (Ser473) polyclonal antiserum, antiphospho-speci®c Cdc2 (Cdk1) (Tyr15) polyclonal antiserum (New England Biolabs MA, USA), anti-Cdc2 polyclonal antiserum (Gibco), anti-cyclin A polyclonal antiserum (Lisztwan et al., 1998, supplied by W Krek, FMI), and anti cyclin B1 polyclonal antiserum, H-433 (Santa Cruz).. Speci®c kinase inhibitors were stored as 1000 ± 5000 times concentrated stock solutions in DMSO and usually added 90 min prior to ligand treatment.Speci®c kinase inhibitors were stored as 1000 ± 5000 times concentrated stock solutions in..

    SDS Page:

    Article Title: NDF/heregulin-induced cell cycle changes and apoptosis in breast tumour cells: role of PI3 kinase and p38 MAP kinase pathways.
    Article Snippet: Recombinant human ErbB ligands included NDF (Neomarkers, Fremont, CA, USA), EGF (Sigma) and BTC (R & D Systems).included NDF (Neomarkers, Fremont, CA, USA), EGF (Sigma) and BTC (R & D Systems). ... Antibodies used were: ErbB2 speci®c 21N polyclonal antiserum (Hynes et al., 1989), ErbB3 speci®c a nity-puri®ed polyclonal antiserum C17 (Santa Cruz Biotechnology), phosphotyrosine-speci®c mAb, p85-speci®c antiserum (UBI), c-Src speci®c Ab-1 mAb (Calbiochem), anti-phospho-speci®c p38a and p38b/b2 MAPK (Thr180/ Tyr182) polyclonal antiserum, anti-phospho-speci®c p44/42 ERK (Thr202/Tyr204) polyclonal antiserum, anti-phosphospeci®c Akt/PKB (Ser473) polyclonal antiserum, antiphospho-speci®c Cdc2 (Cdk1) (Tyr15) polyclonal antiserum (New England Biolabs MA, USA), anti-Cdc2 polyclonal antiserum (Gibco), anti-cyclin A polyclonal antiserum (Lisztwan et al., 1998, supplied by W Krek, FMI), and anti cyclin B1 polyclonal antiserum, H-433 (Santa Cruz).. Speci®c kinase inhibitors were stored as 1000 ± 5000 times concentrated stock solutions in DMSO and usually added 90 min prior to ligand treatment.Speci®c kinase inhibitors were stored as 1000 ± 5000 times concentrated stock solutions in..

    Membrane:

    Article Title: NDF/heregulin-induced cell cycle changes and apoptosis in breast tumour cells: role of PI3 kinase and p38 MAP kinase pathways.
    Article Snippet: Recombinant human ErbB ligands included NDF (Neomarkers, Fremont, CA, USA), EGF (Sigma) and BTC (R & D Systems).included NDF (Neomarkers, Fremont, CA, USA), EGF (Sigma) and BTC (R & D Systems). ... Antibodies used were: ErbB2 speci®c 21N polyclonal antiserum (Hynes et al., 1989), ErbB3 speci®c a nity-puri®ed polyclonal antiserum C17 (Santa Cruz Biotechnology), phosphotyrosine-speci®c mAb, p85-speci®c antiserum (UBI), c-Src speci®c Ab-1 mAb (Calbiochem), anti-phospho-speci®c p38a and p38b/b2 MAPK (Thr180/ Tyr182) polyclonal antiserum, anti-phospho-speci®c p44/42 ERK (Thr202/Tyr204) polyclonal antiserum, anti-phosphospeci®c Akt/PKB (Ser473) polyclonal antiserum, antiphospho-speci®c Cdc2 (Cdk1) (Tyr15) polyclonal antiserum (New England Biolabs MA, USA), anti-Cdc2 polyclonal antiserum (Gibco), anti-cyclin A polyclonal antiserum (Lisztwan et al., 1998, supplied by W Krek, FMI), and anti cyclin B1 polyclonal antiserum, H-433 (Santa Cruz).. Speci®c kinase inhibitors were stored as 1000 ± 5000 times concentrated stock solutions in DMSO and usually added 90 min prior to ligand treatment.Speci®c kinase inhibitors were stored as 1000 ± 5000 times concentrated stock solutions in..

    Comparison:

    Article Title: NDF/heregulin-induced cell cycle changes and apoptosis in breast tumour cells: role of PI3 kinase and p38 MAP kinase pathways.
    Article Snippet: Recombinant human ErbB ligands included NDF (Neomarkers, Fremont, CA, USA), EGF (Sigma) and BTC (R & D Systems).included NDF (Neomarkers, Fremont, CA, USA), EGF (Sigma) and BTC (R & D Systems). ... Antibodies used were: ErbB2 speci®c 21N polyclonal antiserum (Hynes et al., 1989), ErbB3 speci®c a nity-puri®ed polyclonal antiserum C17 (Santa Cruz Biotechnology), phosphotyrosine-speci®c mAb, p85-speci®c antiserum (UBI), c-Src speci®c Ab-1 mAb (Calbiochem), anti-phospho-speci®c p38a and p38b/b2 MAPK (Thr180/ Tyr182) polyclonal antiserum, anti-phospho-speci®c p44/42 ERK (Thr202/Tyr204) polyclonal antiserum, anti-phosphospeci®c Akt/PKB (Ser473) polyclonal antiserum, antiphospho-speci®c Cdc2 (Cdk1) (Tyr15) polyclonal antiserum (New England Biolabs MA, USA), anti-Cdc2 polyclonal antiserum (Gibco), anti-cyclin A polyclonal antiserum (Lisztwan et al., 1998, supplied by W Krek, FMI), and anti cyclin B1 polyclonal antiserum, H-433 (Santa Cruz).. Speci®c kinase inhibitors were stored as 1000 ± 5000 times concentrated stock solutions in DMSO and usually added 90 min prior to ligand treatment.Speci®c kinase inhibitors were stored as 1000 ± 5000 times concentrated stock solutions in..

    Transduction:

    Article Title: NDF/heregulin-induced cell cycle changes and apoptosis in breast tumour cells: role of PI3 kinase and p38 MAP kinase pathways.
    Article Snippet: Recombinant human ErbB ligands included NDF (Neomarkers, Fremont, CA, USA), EGF (Sigma) and BTC (R & D Systems).included NDF (Neomarkers, Fremont, CA, USA), EGF (Sigma) and BTC (R & D Systems). ... Antibodies used were: ErbB2 speci®c 21N polyclonal antiserum (Hynes et al., 1989), ErbB3 speci®c a nity-puri®ed polyclonal antiserum C17 (Santa Cruz Biotechnology), phosphotyrosine-speci®c mAb, p85-speci®c antiserum (UBI), c-Src speci®c Ab-1 mAb (Calbiochem), anti-phospho-speci®c p38a and p38b/b2 MAPK (Thr180/ Tyr182) polyclonal antiserum, anti-phospho-speci®c p44/42 ERK (Thr202/Tyr204) polyclonal antiserum, anti-phosphospeci®c Akt/PKB (Ser473) polyclonal antiserum, antiphospho-speci®c Cdc2 (Cdk1) (Tyr15) polyclonal antiserum (New England Biolabs MA, USA), anti-Cdc2 polyclonal antiserum (Gibco), anti-cyclin A polyclonal antiserum (Lisztwan et al., 1998, supplied by W Krek, FMI), and anti cyclin B1 polyclonal antiserum, H-433 (Santa Cruz).. Speci®c kinase inhibitors were stored as 1000 ± 5000 times concentrated stock solutions in DMSO and usually added 90 min prior to ligand treatment.Speci®c kinase inhibitors were stored as 1000 ± 5000 times concentrated stock solutions in..



    Similar Products

    erbb3 (her3)-speci c sirnas (5’-gcugagaaccaauaccaga and 5’-ccaagggcccaaucuacaa)  (Millipore)
    90
    Millipore erbb3 (her3)-speci c sirnas (5’-gcugagaaccaauaccaga and 5’-ccaagggcccaaucuacaa)
    Erbb3 (Her3) Speci C Sirnas (5’ Gcugagaaccaauaccaga And 5’ Ccaagggcccaaucuacaa), supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/erbb3+speci+c/anti+erbb3/ppr0762924-199-7-28
    Average 90 stars, based on 1 article reviews
    erbb3 (her3)-speci c sirnas (5’-gcugagaaccaauaccaga and 5’-ccaagggcccaaucuacaa) - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    erbb3 speci c  (Santa Cruz Biotechnology)
    93
    Santa Cruz Biotechnology erbb3 speci c
    Figure 3 Tyrosine phosphorylation of <t>ErbB3</t> in response to NDF and BTC but not EGF. SKBR3 cells were treated with 1 nM of the indicated ligands for 10 min and lysed. ErbB3 was immunoprecipitated from 1 mg total lysate using C17 antiserum, subjected to SDS ± PAGE, blotted and probed with an anti- phosphotyrosine mAb. The membrane was then stripped and reprobed with ErbB3 speci®c C17 serum
    Erbb3 Speci C, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/erbb3+speci+c/ErbB-3+Antibody/pm10376522-257-12-19
    Average 93 stars, based on 1 article reviews
    erbb3 speci c - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    Figure 3 Tyrosine phosphorylation of ErbB3 in response to NDF and BTC but not EGF. SKBR3 cells were treated with 1 nM of the indicated ligands for 10 min and lysed. ErbB3 was immunoprecipitated from 1 mg total lysate using C17 antiserum, subjected to SDS ± PAGE, blotted and probed with an anti- phosphotyrosine mAb. The membrane was then stripped and reprobed with ErbB3 speci®c C17 serum

    Journal: Oncogene

    Article Title: NDF/heregulin-induced cell cycle changes and apoptosis in breast tumour cells: role of PI3 kinase and p38 MAP kinase pathways.

    doi: 10.1038/sj.onc.1202700

    Figure Lengend Snippet: Figure 3 Tyrosine phosphorylation of ErbB3 in response to NDF and BTC but not EGF. SKBR3 cells were treated with 1 nM of the indicated ligands for 10 min and lysed. ErbB3 was immunoprecipitated from 1 mg total lysate using C17 antiserum, subjected to SDS ± PAGE, blotted and probed with an anti- phosphotyrosine mAb. The membrane was then stripped and reprobed with ErbB3 speci®c C17 serum

    Article Snippet: Antibodies used were: ErbB2 speci®c 21N polyclonal antiserum (Hynes et al., 1989), ErbB3 speci®c a nity-puri®ed polyclonal antiserum C17 (Santa Cruz Biotechnology), phosphotyrosine-speci®c mAb, p85-speci®c antiserum (UBI), c-Src speci®c Ab-1 mAb (Calbiochem), anti-phospho-speci®c p38a and p38b/b2 MAPK (Thr180/ Tyr182) polyclonal antiserum, anti-phospho-speci®c p44/42 ERK (Thr202/Tyr204) polyclonal antiserum, anti-phosphospeci®c Akt/PKB (Ser473) polyclonal antiserum, antiphospho-speci®c Cdc2 (Cdk1) (Tyr15) polyclonal antiserum (New England Biolabs MA, USA), anti-Cdc2 polyclonal antiserum (Gibco), anti-cyclin A polyclonal antiserum (Lisztwan et al., 1998, supplied by W Krek, FMI), and anti cyclin B1 polyclonal antiserum, H-433 (Santa Cruz).

    Techniques: Phospho-proteomics, Immunoprecipitation, SDS Page, Membrane

    Figure 5 Comparison of signal transduction by NDF and BTC. SKBR3 cells were treated with 1 nM of NDF or BTC for the indicated times or left untreated (con). (a, b) 70 mg total lysate was subjected to SDS ± PAGE, blotted and probed with antisera speci®c for the active forms of ERK 1 and 2 (a). The blot was stripped and then probed for the active forms p38 MAPK (b). (c) ErbB3 was immunoprecipitated from 1 mg total lysate, subjected to SDS ± PAGE, blotted and probed with antiserum speci®c for the p85 subunit of PI3K. (d) 50 mg total lysate was subjected to SDS ± PAGE, blotted and probed with antisera speci®c for the active form of PKB

    Journal: Oncogene

    Article Title: NDF/heregulin-induced cell cycle changes and apoptosis in breast tumour cells: role of PI3 kinase and p38 MAP kinase pathways.

    doi: 10.1038/sj.onc.1202700

    Figure Lengend Snippet: Figure 5 Comparison of signal transduction by NDF and BTC. SKBR3 cells were treated with 1 nM of NDF or BTC for the indicated times or left untreated (con). (a, b) 70 mg total lysate was subjected to SDS ± PAGE, blotted and probed with antisera speci®c for the active forms of ERK 1 and 2 (a). The blot was stripped and then probed for the active forms p38 MAPK (b). (c) ErbB3 was immunoprecipitated from 1 mg total lysate, subjected to SDS ± PAGE, blotted and probed with antiserum speci®c for the p85 subunit of PI3K. (d) 50 mg total lysate was subjected to SDS ± PAGE, blotted and probed with antisera speci®c for the active form of PKB

    Article Snippet: Antibodies used were: ErbB2 speci®c 21N polyclonal antiserum (Hynes et al., 1989), ErbB3 speci®c a nity-puri®ed polyclonal antiserum C17 (Santa Cruz Biotechnology), phosphotyrosine-speci®c mAb, p85-speci®c antiserum (UBI), c-Src speci®c Ab-1 mAb (Calbiochem), anti-phospho-speci®c p38a and p38b/b2 MAPK (Thr180/ Tyr182) polyclonal antiserum, anti-phospho-speci®c p44/42 ERK (Thr202/Tyr204) polyclonal antiserum, anti-phosphospeci®c Akt/PKB (Ser473) polyclonal antiserum, antiphospho-speci®c Cdc2 (Cdk1) (Tyr15) polyclonal antiserum (New England Biolabs MA, USA), anti-Cdc2 polyclonal antiserum (Gibco), anti-cyclin A polyclonal antiserum (Lisztwan et al., 1998, supplied by W Krek, FMI), and anti cyclin B1 polyclonal antiserum, H-433 (Santa Cruz).

    Techniques: Comparison, Transduction, SDS Page, Immunoprecipitation